Management of HER2-Low Metastatic Breast Cancer: A Comprehensive Statement by an Expert Group from the Middle East and Africa Region
Approximately 50 to 67% of breast cancers (BCs), traditionally categorized as human epidermal growth factor receptor 2 (HER2)-negative, but demonstrating low HER2 expression, are now being defined as a new HER2-low subset or HER2-low category of BC. For metastatic BC (mBC), standard therapy options...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Shiraz University of Medical Sciences
2025-10-01
|
| Ráidu: | Middle East Journal of Cancer |
| Fáttát: | |
| Liŋkkat: | https://mejc.sums.ac.ir/article_50590_31ce17421f15ccce87c42b6fa6221037.pdf |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|